Targeting lipid-lowering drug therapy for primary prevention of coronary disease: An updated Sheffield table

Lancet

Volumn 348, Issue 9024, 1996, Pages 387-388

  Ramsay, L E ^a   Haq, I U ^a   Jackson, P R ^a   Yeo, W W ^a   Pickin, D M ^b   Payne, J N ^c  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b Medical Care Research Unit   (United Kingdom)

^c Department of Public Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; SIMVASTATIN;

ADULT; AGED; CHOLESTEROL BLOOD LEVEL; DRUG TARGETING; HUMAN; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SHORT SURVEY;

EID: 0030578660     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)05516-X     Document Type: Article

References (5)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89.
2. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl. J Med 1995; 333: 1301-07.
3. Haq IU, Ramsay LE, Pickin DM, Yeo WW, Jackson PR. Payne JN. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (in press).
4. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1467-71.
5. Grover SA, Coupal L, Hu X-P. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? JAMA 1995; 274: 801-06.